# US 2021/0069259 A1 · Compositions and methods for treating skin infections and other diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069259 A1
- Document ID: US20210069259A1
- Status: Published application
- Kind: A1
- Application number: 16/935,899
- Filed: 2020-07-22
- Published: 2021-03-11
- Earliest claimed: 2019-07-18
- Inventors: Huiying Li; Mizue Naito
- Web page: https://patentgrep.com/patent/US20210069259A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61P 17/10: Anti-acne agents
- A61P 31/04: Antibacterial agents
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods and compositions for promoting skin health.

## Claims

### Claim 1

A method of treating or preventing a disease in a subject in need thereof, comprising administering a composition comprising a Propionibacterium bacterium that comprises Locus 4 to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Propionibacterium bacterium is P. acnes.

### Claim 3 (depends on 2)

The method of claim 2, wherein the Propionibacterium acnes bacterium is a P. acnes strain selected from HL037PA1, HL078PA1, HL053PA2, HL082PA1, HL086PA1, HL092PA1, HL110PA1, HL110PA2, HL030PA2, HL030PA1, HL063PA2, PV-66, Type IA2 P.acn17, HL097PA1, PRP-38, 5_U_42AFAA, and HL082PA2

### Claim 4 (depends on 2)

The method of claim 2, wherein the P. acnes is RT8, RT1, RT3, or RT5 P. acnes.

### Claim 5 (depends on 2)

The method of claim 2, wherein the P. acnes belongs to the IB-1, IB-2, or IC clade.

### Claim 6 (depends on 1)

The method of claim 1, wherein the Propionibacterium bacterium is P. avidum.

### Claim 7 (depends on 6)

The method of claim 6, wherein the Propionibacterium avidum is P. avidum strain HL083PV1 or HGH0353.

### Claim 8 (depends on 1)

The method of claim 1, wherein the a Propionibacterium bacterium encodes for an amino acid sequence with at least 80% homology to any one of the amino acid sequences set forth in SEQ ID NO: 1-5 or 7-14.

### Claim 9 (depends on 1)

The method of claim 1, wherein the disease is a caused by Gram-positive bacteria.

### Claim 10 (depends on 9)

The method of claim 9, wherein the Gram positive bacteria is Staphylococcus.

### Claim 11 (depends on 10)

The method of claim 10, wherein the Staphylococcus bacteria is Methicillin-resistant Staphylococcus aureus (MRSA).

### Claim 12 (depends on 9)

The method of claim 9, wherein the Gram positive bacteria is Enterococcus.

### Claim 13 (depends on 12)

The method of claim 12, wherein the Enterococcus bacteria is Vancomycin-resistant Enterococcus (VRE).

### Claim 14 (depends on 9)

The method of claim 9, wherein the Gram positive bacteria is Streptococcus.

### Claim 15 (depends on 14)

The method of claim 14, wherein the Streptococcus bacteria is Group A Streptococcus (GAS).

### Claim 16 (depends on 9)

The method of claim 9, wherein the Gram positive bacteria is C. difficile, P. acnes, P. avidum, P. granulosum, or P. humerusii.

### Claim 17 (depends on 1)

The method of claim 1, wherein the disease is a skin disease associated with inflammation.

### Claim 18 (depends on 17)

The method of claim 17, wherein the skin disease associated with inflammation is atopic dermatitis, psoriasis, or acne.

### Claim 19 (depends on 1)

The method of claim 1, wherein the Propionibacterium bacterium produces agent X.

### Claim 20 (depends on 1)

The method of claim 1, wherein the composition comprising Propionibacterium bacterium that comprises Locus 4 is heat treated, tyndallized or supernatant-derived.

### Claim 21 (depends on 1)

The method of claim 1, wherein the composition is formulated for topical delivery.

### Claim 22

A method of treating or preventing an infection caused by Gram-positive bacteria in a subject in need thereof, comprising administering a composition comprising a Propionibacterium bacterium that comprises Locus 4 to the subject.

### Claim 23

A method of reducing the levels of a Gram-positive bacteria on the skin of a subject in need thereof, comprising administering a composition comprising a Propionibacterium bacterium that comprises Locus 4 to the subject.

### Claim 24 (depends on 22)

The method of claim 22, wherein the Propionibacterium bacterium is P. acnes.

### Claim 25 (depends on 24)

The method of claim 24, wherein the Propionibacterium acnes bacterium is a P. acnes strain selected from HL037PA1, HL078PA1, HL053PA2, HL082PA1, HL086PA1, HL092PA1, HL110PA1, HL110PA2, HL030PA2, HL030PA1, HL063PA2, PV-66, Type IA2 P.acn17, HL097PA1, PRP-38, 5_U_42AFAA, and HL082PA2.

### Claim 26 (depends on 22)

The method of claim 22, wherein the Propionibacterium bacterium is P. avidum.

### Claim 27 (depends on 26)

The method of claim 26, wherein the Propionibacterium avidum is P. avidum strain HL083PV1 or HGH0353.

### Claim 28 (depends on 22)

The method of claim 22, wherein the a Propionibacterium bacterium encodes for an amino acid sequence with at least 80% homology to any one of the amino acid sequences set forth in SEQ ID NO: 1-5 or 7-14.

### Claim 29 (depends on 22)

The method of claim 22, wherein the composition comprising Propionibacterium bacterium that comprises Locus 4 is heat treated, tyndallized or supernatant-derived.

### Claim 30 (depends on 22)

The method of claim 22, wherein the compositions formulated for topical delivery.
